S2 Fig. Analysis of blood cells in tumour-bearing mice before and after treatment with A2M

**(a)** Coarse of body weight of tumour-bearing A549 mice treated with A2M\* (*n* = 10) compared to control (*n* = 9). **(b)** EDTA blood was withdrawn from A549 tumour bearing mice and analysed in a ScilVet apparatus (ScilVet Animal Care Company, Viernheim, Germany). Blood cells were counted at day 7 after tumour induction (control) and day 31 after A2M\* treatment. WBC – white blood cells, RBC – red blood cells, HGB - Hemoglobin, HCT – Hematocrit value, MCV – mean corpuscular volume, MCH – mean corpuscular hematocrit, PLT - platelets, MPV – mean platelet volume, RDW – red cell distribution width, LYM – Lymphocytes, MO - Monocytes, GRA - Granulocytes, (*n* = 9), (\* *P < 0.05*, \*\**P < 0.01*, \*\*\**P < 0.001*). **(c),** Effect of A2M\* on mouse spleen cells. Spleen cells from A549 tumour-bearing mice treated with A2M\* were isolated, stimulated with 10 nM lipopolysaccharide (LPS) or PBS (control) and cytokines were measured by cytokine bead arrays (CBA). (*n* = 10) (\*\**P < 0.01*). Error bars represent mean ± s.d.